S. Schmitz

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)

W. Hiddemann, C. Huber, M. Dreyling, 2007, Leukemia & lymphoma.

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

G. Mufti, K. Götze, W. Hofmann, 2014 .

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy.

L. Pientka, U. Wedding, H. Steinmetz, 2007, Critical reviews in oncology/hematology.

Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia – examination of practice in Germany

H. Tesch, A. Tsamaloukas, U. Totzke, 2008 .

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).

W. Hiddemann, C. Huber, M. Dreyling, 2006 .

Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival

H. Tesch, R. Liersch, U. Totzke, 2023, Leukemia & lymphoma.